1. Lundbeck, H.: FDA accepts Takeda and Lundbeck’s filing for review of Brintellix (vortioxetine) for the treatment of major depression.
http://investor.lundbeck.com/releasedetail.cfm?releaseid=726533
(2012)
2. Lundbeck, H.: BRINTELLIX™ (vortioxetine) tablets for oral use. Full Prescribing Information. Pharmacodynamics (2013)
3. Kelliny, M., Croarkin, P.E., Moore, K.M., Bobo, W.V.: Profile of vortioxetine in the treatment of major depressive disorder: an overview of the primary and secondary literature. Ther. Clin. Risk Manag. 11, 1193–1212 (2015)
4. Kohler, S., Cierpinsky, K., Kronenberg, G., Adli, M.: The serotonergic system in the neurobiology of depression: relevance for novel antidepressants. J. Psychopharm. 30(1), 13–22 (2016)
5. Rothschild, A.J., Mahableshwarkar, A.R., Jacobsen, P., Yan, M., Sheehan, D.V.: Vortioxetine (Lu AA21004) 5 mg in generalized anxiety disorder: results of an 8-week randomized, double-blind, placebo-controlled clinical trial in the United States. Eur. Neuropsychopharm. 22(12), 858–866 (2012)